Blood test to watch for liver cancer return
Part of Cancer, Digestive system clinical trials.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- Your diagnosis follows standard guidelines from liver disease experts.
- You have at least one tumor that can be measured on a scan.
- Your doctor expects you to live for 12 weeks or more.
- You are willing to sign a consent form and follow the study plan.
- You do not have other active cancers or serious medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test that looks for signs of liver cancer coming back after treatment. It may help doctors find recurrence early and plan better care.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This study looks at whether a blood test (measuring a protein called AKR1B10) can help detect if liver cancer comes back after surgery. It may help doctors monitor patients more closely after tumor removal.
This trial studies a new blood test that looks for bits of tumor DNA (ct-mtDNA) to see if it can detect if biliary tract cancer has come back earlier than standard scans. The test might help doctors monitor for recurrence more closely.
This trial studies whether a blood test can predict if liver cancer comes back after surgery or ablation, and whether an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence. It may help guide treatment to keep the cancer from returning.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.